NYSE : BMY

Bristol-Myers Squibb Company

$62.09 USD

$0.58 (0.94%)

Volume
11.98M
Average Volume
11.82M
Market Capitalization
$126.79B
P/E Ratio
17.44
Dividend Yield
4.04%
Price Target
$65.00
Year High
$62.89
Year Low
$42.52
Day High
—
Day Low
—
Payout Ratio
$0.70
Current Ratio
$1.42
Company Overview

NYSE

Christopher S. Boerner

Drug Manufacturers - General

Healthcare

BMY

32500

US

USD

https://www.bms.com

609 252 4621

110122108

0000014272

Liquidity Metrics

2.22

1.42

1.28

0.50

0.70

Sales & Valuation

$48.19B

2.62

6.32

10.65

5.83

Profitability

$3.45

$7.05B

15.01%

19.79%

39.05%

8.41%

P/E Metrics

17.44

0.53

0.53

Analyst Price Target & Rating

$65.00

$75.00

$40.00

Neutral

3/5

41 Analysts

-4.48%

Financial Health Scores

2.50

8/9

$8.05B

$86.48B

$66.37B

$10.46B

Key Metrics (TTM)

$161.68B

3.33

11.76

1.42

39.05%

13.55%

5.73%

9.39%

$28.05

55 days

Company Executives
Name Title
David V. Elkins Executive Vice President & Chief Financial Officer
Cristian Massacesi Executive Vice President, Chief Medical Officer & Head of Development
Greg Meyers Executive Vice President and Chief Digital & Technology Officer
Karin Shanahan Executive Vice President, Chief Supply Chain & Operations Officer
Adam Lenkowsky Executive Vice President & Chief Commercialization Officer
Ahn Amanda Poole Executive Vice President & Chief People Officer
Christopher S. Boerner Chief Executive Officer & Chairman
Cari Gallman Executive Vice President, General Counsel & Chief Policy Officer
Joseph J. Eiden Jr. Head of Medical Affairs
Charles E. Triano SVP & Head of Investor Relations
Poll Results

No votes yet today — be the first to share your view!

About Bristol-Myers Squibb Company (NYSE:BMY) Stock

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for mul ... tiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.

Buy 4 Barron's Better Bets (Than T-Bills) Out Of 11 'Safer' July DiviDogs

2026-07-26 06:27:24

Verizon , Kinder Morgan, Regions Financial, and KeyCorp are the four buyable Barron's Better Bets Dogs, offering high, 'safest' dividends at fair prices. Analyst forecasts project net gains of 9.62% to 21.97% for top BBB Dogs by July 2027, with average net 13.68% on the top ten. Six BBB Dogs show negative free cash flow margins, making their dividends potentially unsafe; Pfizer, ONEOK, Mid-America Apartment, Federal Realty, Williams Companies, and Entergy are flagged.

Israel "Izzy" Englander Increased His Position in This Pharma Stock by 780%. Does He Know Something Wall Street Doesn't?

2026-07-26 04:42:00

Analysts aren't nearly as bullish about Bristol Myers Squibb as this billionaire hedge fund manager is.

Bank of Nova Scotia Sells 50,416 Shares of Bristol Myers Squibb Company $BMY

2026-07-25 04:05:41

Bank of Nova Scotia decreased its stake in shares of Bristol Myers Squibb Company (NYSE: BMY) by 6.3% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 752,756 shares of the biopharmaceutical company's stock after selling 50,416 shares during the

Is Bristol Myers Squibb's Dividend Too Good to Be True? Here's My Honest Answer

2026-07-24 16:30:00

Bristol Myers Squibb can easily fund its dividend with earnings and free cash flow. A looming patent cliff -- a legitimate concern -- explains why the yield is creeping higher.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

2026-07-24 09:56:06

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Aureus Asset Management LLC Decreases Position in Bristol Myers Squibb Company $BMY

2026-07-24 03:51:17

Aureus Asset Management LLC cut its holdings in Bristol Myers Squibb Company (NYSE: BMY) by 81.3% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,689 shares of the biopharmaceutical company's stock after selling 15,997 shares during the period. Aureus Asset

Bristol Myers Squibb (BMY) Rises As Market Takes a Dip: Key Facts

2026-07-23 18:46:17

In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $61.4, denoting a +1.05% move from the preceding trading day.

Bristol Myers Squibb (BMY) Reports Next Week: Wall Street Expects Earnings Growth

2026-07-23 11:02:06

Bristol Myers (BMY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Frequently Asked Questions

What is the current Bristol-Myers Squibb Company (BMY) stock price?

Bristol-Myers Squibb Company(NYSE:BMY) stock price is $62.09 in the last trading session. During the trading session, BMY stock reached the peak price of $62.89 while $42.52 was the lowest point it dropped to. The percentage change in BMY stock occurred in the recent session was 0.94% while the dollar amount for the price change in BMY stock was $0.58.

BMY's industry and sector of operation?

The NYSE listed BMY is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector.

Who are the executives of BMY?

David V. Elkins | Executive Vice President & Chief Financial Officer
Cristian Massacesi | Executive Vice President, Chief Medical Officer & Head of Development
Greg Meyers | Executive Vice President and Chief Digital & Technology Officer
Karin Shanahan | Executive Vice President, Chief Supply Chain & Operations Officer
Adam Lenkowsky | Executive Vice President & Chief Commercialization Officer

How many employees does BMY have?

Number of BMY employees currently stands at 32500. BMY operates from Route 206 & Province Line Road, Princeton, NJ 08543, US.

Link for BMY official website?

Official Website of BMY is: https://www.bms.com

How do I contact BMY?

BMY could be contacted at phone #609 252 4621 and can also be accessed through its website. BMY operates from Route 206 & Province Line Road, Princeton, NJ 08543, US.

How many shares of BMY are traded daily?

The average number of BMY shares traded daily for last 3 months was 11.82M.

What is the market cap of BMY currently?

The market value of BMY currently stands at $126.79B with its latest stock price at $62.09